top of page
eracal

overcoming the metabolic syndrome

eracal

redalpine

preventing the onset of obesity-related diseases

obesity is one of the most widespread diseases of the 21st century and comes with a high risk of cardiovascular disease, type 2 diabetes, cancer, and reduced life expectancy. treating obesity with drugs has, so far, not been effective, often resulting in unwanted side effects and failing to prevent the onset of obesity-associated complications.

potent, effective appetite suppressants

eracal closes this gap by developing potent and highly selective appetite suppressants, with animal models showing superior effectiveness at reducing weight over current drugs on the market. eracal was spun out of the university of zurich and harvard university in 2018.

related stories

Sep 10, 2020

Redalpine companies score at the TOP 100 Swiss Startup Award 2020

Oct 16, 2019

Appetite for EraCal: Redalpine invests in the Seed round

bottom of page